Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-2 in CD25 Positive Chronic Lymphocytic Leukemia
NCT00077922Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2004
- Primary completion
- Dec 2011
- Modality
- Immunotoxins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LMB-2 in chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL), sponsored by National Cancer Institute. Primary endpoint: Response Rate up to 7 months. Started Feb 2004; status: completed.
02
Drugs
LMB-2
03
Conditions
chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT00077922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077922.